Kimura Miyuna, Yamauchi Junji, Sato Tomoo, Yagishita Naoko, Araya Natsumi, Aratani Satoko, Tanabe Kenichiro, Horibe Erika, Watanabe Toshiki, Coler-Reilly Ariella, Nagasaka Misako, Akasu Yukari, Kaburagi Kei, Kikuchi Takayuki, Shibata Soichiro, Matsumoto Hirofumi, Koseki Akihito, Inoue Soichiro, Takata Ayako, Yamano Yoshihisa
Department of Anesthesiology, St. Marianna University School of Medicine, Kawasaki, Japan.
Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan.
Front Med (Lausanne). 2022 Apr 11;9:879379. doi: 10.3389/fmed.2022.879379. eCollection 2022.
Human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy (HAM) is a neuroinflammatory disease, causing various neurological symptoms, including motor, sensory, and bladder and bowel dysfunctions. This study was designed to reveal the impact of HAM and related symptoms on health-related quality of life (HRQoL).
We analyzed the Short Form-36 (SF-36) and clinical data of 538 patients with HAM registered in the HAM-net, a nationwide patient registry for HAM in Japan. HRQoL was evaluated using the SF-6D (a health state utility value calculated from the SF-36) and eight SF-36 subscales. A general liner model was used to estimate the impact of major HAM-related symptoms, including gait dysfunction, sensory disturbance in the legs (pain and numbness), urinary dysfunction, and constipation, on the SF-6D and SF-36 subscale scores.
The mean age and disease duration were 62.0 and 16.5 years, respectively. Of the patients, 73.2% needed walking aid; 42.7 and 67.1% had leg pain and numbness, respectively; 92.1% had urinary dysfunction; and 77.9% had constipation. The mean SF-6D score was 0.565, which was significantly lower than the national average (0.674 in the 60-69 years age group; < 0.001), exceeding the minimal important difference (0.05-0.1). All the major symptoms were significantly associated with a decrease in the SF-6D score. The SF-36 subscale scores were significantly lower than the national standard of 50 ( ≤ 0.001), except for mental health (MH). Gait dysfunction was associated with lower scores in physical functioning (PF), limitations on role functioning because of physical health, bodily pain, general health perception (GH), vitality (VT), and social functioning; however, no association was observed between gait dysfunction and limitations on role functioning because of emotional problems and MH. Meanwhile, sensory disturbance in the legs was associated with a decrease in scores in all subscales. Urinary dysfunction was associated with worse PF, GH, VT, and MH. Constipation was associated only with PF.
HRQoL of patients with HAM was worse than that of the general population and was associated with all major symptoms. Thus, patients should be comprehensively managed to achieve better HRQoL.
1型人类嗜T淋巴细胞病毒(HTLV-1)相关脊髓病(HAM)是一种神经炎症性疾病,可导致多种神经症状,包括运动、感觉以及膀胱和肠道功能障碍。本研究旨在揭示HAM及其相关症状对健康相关生活质量(HRQoL)的影响。
我们分析了日本全国性HAM患者登记系统HAM-net中登记的538例HAM患者的简明健康状况调查量表(SF-36)及临床数据。使用SF-6D(一种根据SF-36计算得出的健康状态效用值)和8个SF-36子量表对HRQoL进行评估。采用一般线性模型来估计主要的HAM相关症状,包括步态功能障碍、腿部感觉障碍(疼痛和麻木)、排尿功能障碍和便秘,对SF-6D和SF-36子量表评分的影响。
患者的平均年龄和病程分别为62.0岁和16.5年。患者中,73.2%需要借助步行辅助工具;分别有42.7%和67.1%的患者有腿部疼痛和麻木;92.1%有排尿功能障碍;77.9%有便秘。SF-6D的平均评分为0.565,显著低于全国平均水平(60 - 69岁年龄组为0.674;P < 0.001),超过了最小重要差异(0.05 - 0.1)。所有主要症状均与SF-6D评分降低显著相关。除心理健康(MH)外,SF-36子量表评分均显著低于国家标准50(P ≤ 0.001)。步态功能障碍与身体功能(PF)、因身体健康导致的角色功能受限、身体疼痛、总体健康感知(GH)、活力(VT)和社会功能得分较低相关;然而,未观察到步态功能障碍与因情绪问题和MH导致的角色功能受限之间存在关联。同时,腿部感觉障碍与所有子量表得分降低相关。排尿功能障碍与较差的PF、GH、VT和MH相关。便秘仅与PF相关。
HAM患者的HRQoL比一般人群差,且与所有主要症状相关。因此,应对患者进行全面管理以实现更好的HRQoL。